46
Participants
Start Date
February 14, 2024
Primary Completion Date
December 1, 2025
Study Completion Date
June 25, 2026
BI 764532
BI 764532
Carboplatin
Carboplatin
Etoposide
Etoposide
Atezolizumab
Atezolizumab
Durvalumab
Durvalumab
Cisplatin
Cisplatin
University Hospital of Lausanne, Lausanne
Cliniques Universitaires Saint-Luc, Brussels
Kortrijk - HOSP AZ Groeninge Kennedylaan, Kortrijk
Hospital Universitario Ramon Y Cajal, Madrid
Fundación Jiménez Díaz, Madrid
Emory University, Atlanta
Orlando Health Cancer Institute, Orlando
INS Bergonie, Bordeaux
Universitätsklinikum Gießen und Marburg GmbH, Giessen
Hospital Virgen Macarena, Seville
Instituto Valenciano de Oncología, Valencia
Hospital Clínico de Valencia, Valencia
HOP Civil, Strasbourg
HOP Louis Pradel, Bron
INS Gustave Roussy, Villejuif
Saitama Medical University International Medical Center, Saitama, Hidaka
Hamamatsu University Hospital, Shizuoka, Hamamatsu
National Cancer Center Hospital, Tokyo, Chuo-ku
Japanese Foundation for Cancer Research, Tokyo, Koto-ku
Medical University Gdansk, Gdansk
Polish Mother's Memorial Hospital - Research Institute, Lodz
MED POLONIA SP Z O O, Clinical Trials Department,Poznan, Poznan
Lead Sponsor
Boehringer Ingelheim
INDUSTRY